| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1515/CCLM.2011.707 |
| P698 | PubMed publication ID | 21919545 |
| P2093 | author name string | Gregory J Tsongalis | |
| Laura J Tafe | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event | Q28245213 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients | Q33305210 | ||
| Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. | Q33751191 | ||
| HER2-positive circulating tumor cells in breast cancer | Q33802925 | ||
| HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial | Q34194672 | ||
| Emerging technologies for assessing HER2 amplification | Q34659152 | ||
| Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches | Q35034555 | ||
| The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer | Q36814238 | ||
| Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists | Q36944264 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations | Q37388937 | ||
| Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 | ||
| Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. | Q38414983 | ||
| Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry | Q38427140 | ||
| Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab | Q38440789 | ||
| Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial | Q39712731 | ||
| Delay to formalin fixation effect on breast biomarkers | Q43280139 | ||
| Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis | Q43294276 | ||
| Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. | Q45935030 | ||
| Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer | Q46755338 | ||
| HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial | Q51751068 | ||
| Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. | Q53060420 | ||
| Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. | Q53067130 | ||
| P433 | issue | 1 | |
| P921 | main subject | Erb-b2 receptor tyrosine kinase 2 | Q415271 |
| P304 | page(s) | 23-30 | |
| P577 | publication date | 2011-09-15 | |
| P1433 | published in | Clinical Chemistry and Laboratory Medicine | Q5133754 |
| P1476 | title | The human epidermal growth factor receptor 2 (HER2). | |
| P478 | volume | 50 |
| Q37341891 | A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression |
| Q38133084 | Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine |
| Q33557258 | Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer |
| Q44056799 | Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients. |
| Q37375636 | Usefulness of traditional serum biomarkers for management of breast cancer patients. |
Search more.